Dementias & Alzheimer’s

Clinical Trial to Evaluate Finger-Prick Blood Test for Alzheimer’s Diagnosis

The study will analyze three key proteins to determine if blood-based biomarkers can provide an earlier and more accessible diagnostic method.

Gut-Derived Blood Markers May Detect Early Cognitive Decline Before Symptoms
Concussion Blood Test Advances Toward FDA Submission With Point-of-Care Collaboration
C2N Diagnostics’ eMTBR-tau243 Plasma Assay Used in Alzheimer’s Phase 3 Trial Dataset
New Ultra-Sensitive Assays Aim to Improve Early Detection of Alzheimer’s and Parkinson’s Disease
Researchers Develop First DNA Aptamers That Bind Alzheimer’s Blood Biomarker Neurofilament Light Chain
ADDF Launches Third Phase of Diagnostics Accelerator with $50 Million to Advance Alzheimer’s Blood Tests and AI Biomarkers
Siemens Healthineers Expands Brain Health Research Portfolio with New Blood-Based Tau Assays
Roche Receives CE Mark for Blood-Based Immunoassay Test to Detect Alzheimer’s Genetic Risk Factor ApoE4
Blood Test ‘Clock’ Predicts Alzheimer’s Symptom Onset Within Years

Dementias & Alzheimer’s

Lucent Diagnostics Partners to Bring Blood-Based Alzheimer’s Testing to Community Settings

The collaboration will expand access to Alzheimer's biomarker testing through mobile delivery to community centers, churches, and senior centers nationwide.

Dementias & Alzheimer’s

ALZpath, Siemens Healthineers Partner on Blood-Based Alzheimer’s Testing

Licensing agreement will integrate ALZpath's pTau217 antibody into Siemens' Atellica analyzer test menu for IVD Alzheimer's diagnostics.

New FDA-Cleared Blood Test Moves Alzheimer’s Assessment into Primary Care

Oct 28, 2025 | Dementias & Alzheimer’s

Roche’s Elecsys pTau181 assay gives clinical labs a key role in the initial evaluation of cognitive decline, helping to rule out amyloid pathology earlier in the diagnostic process.

Study Demonstrates Accuracy of Two Quest Blood Tests for Alzheimer’s Diagnosis

Oct 27, 2025 | Dementias & Alzheimer’s

Two biomarker panels demonstrated 91% sensitivity and specificity in symptomatic patients, potentially reducing the need for PET imaging confirmation.

Labcorp to Offer FDA-Cleared Blood Test for Alzheimer’s Assessment in Primary Care

Oct 23, 2025 | Dementias & Alzheimer’s

The Elecsys pTau181 test measures phosphorylated Tau 181 protein to help rule out Alzheimer’s-related amyloid pathology in patients 55 and older.

FDA Clears Blood Test for Alzheimer’s Assessment in Primary Care

Oct 14, 2025 | Dementias & Alzheimer’s

The test measures phosphorylated Tau 181 protein to help rule out Alzheimer’s-related amyloid pathology in patients 55 and older.

New Blood-Based Assay Targets Brain-Specific Alzheimer’s Biomarker

Oct 10, 2025 | Dementias & Alzheimer’s

The single-plex assay, for research use only, measures brain-derived phosphorylated tau 217 from plasma, serum, and dried blood spots without requiring cerebrospinal fluid collection.

C2N Diagnostics Lowers Age Limit for Alzheimer’s Blood Test to 50

Aug 25, 2025 | Dementias & Alzheimer’s

C2N Diagnostics has expanded the intended use of its PrecivityAD2 Alzheimer’s disease blood test to include patients 50 years and older, lowering the previous age limit from 60 years.

How a New Blood Test and Research Are Aimed at Diagnosing and Preventing Alzheimer’s Disease

Aug 20, 2025 | Dementias & Alzheimer’s

A Rutgers research director outlines clinical applications and limitations of the new diagnostic tool while highlighting the need for specialist interpretation.

First FDA-Cleared Blood Test for Alzheimer’s Disease Launches

Aug 18, 2025 | Dementias & Alzheimer’s

The test offers a less invasive alternative to cerebrospinal fluid testing and PET scans for detecting amyloid plaques.

Korean Researchers Develop SERS Platform 100,000 Times More Sensitive Than ELISA for Alzheimer’s Detection

Aug 18, 2025 | Dementias & Alzheimer’s

The surface-enhanced Raman spectroscopy platform can detect amyloid beta biomarkers at ultra-low concentrations in body fluids, potentially enabling earlier diagnosis and monitoring of disease progression.

pTau217 Antibody Demonstrates Reliability for Alzheimer’s Detection

Aug 12, 2025 | Dementias & Alzheimer’s

ALZpath pTau217 antibody data was included in 37 submissions at AAIC, building on research demonstrating its sensitivity and accuracy in blood-based tests for Alzheimer’s disease.

Blood-Based Biomarker Testing for Alzheimer’s Gets Formal Guidance

Jul 31, 2025 | Dementias & Alzheimer’s

The Alzheimer’s Association released its first clinical practice guideline on the use of blood-based biomarker tests.

AI-Enhanced EEG Promises Early Alzheimer’s Detection

Jul 29, 2025 | Dementias & Alzheimer’s

AI-enhanced EEG technology is emerging as a promising tool for early detection of Alzheimer’s disease, potentially facilitating prevention efforts before symptoms appear.

Roche Shares Alzheimer’s Drug and Diagnostic Advances at AAIC 2025

Jul 28, 2025 | Dementias & Alzheimer’s

At the Alzheimer’s Association International Conference, Roche shared new data on its investigational antibody trontinemab and its Elecsys pTau217 blood test.